Inventor
GUSAROVA VIKTORIA
US16 patents
⚠️ This page may combine multiple inventors who share the name “GUSAROVA VIKTORIA”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
REGENERON PHARMA
15 patentsUS9951127B2Apr 24, 2018
Anti-ANGPTL3 antibodies and uses thereof
REGENERON PHARMA7 citations84
US9120851B2Sep 1, 2015
Human antibodies to human angiopoietin-like protein 4
REGENERON PHARMA11 citations83
US8354103B2Jan 15, 2013
Human antibodies to human angiopoietin-like protein 4
REGENERON PHARMA5 citations83
US10995150B2May 4, 2021
Methods for inhibiting atherosclerosis by administering an anti-PCSK9 antibody
REGENERON PHARMA6 citations79
US10494442B2Dec 3, 2019
Methods for inhibiting atherosclerosis by administering an inhibitor of PCSK9
REGENERON PHARMA9 citations79
US10358487B2Jul 23, 2019
Anti-ANGPTL3 antibodies and uses thereof
REGENERON PHARMA2 citations73
US10259870B2Apr 16, 2019
Anti-ANGPTL8 antibodies and uses thereof
REGENERON PHARMA2 citations72
US10442856B2Oct 15, 2019
Methods of treating obesity with anti-ANGPTL8 antibodies
REGENERON PHARMA1 citations62
US12497460B2Dec 16, 2025
Anti-MSR1 antibodies and methods of use thereof
REGENERON PHARMA0 citations61
US11377502B2Jul 5, 2022
Anti-MSR1 antibodies and methods of use thereof
REGENERON PHARMA1 citations61
US12281173B2Apr 22, 2025
Methods for treating patients with hyperlipidemia by administering a PCSK9 inhibitor in combination with an ANGPTL3 inhibitor
REGENERON PHARMA0 citations52
US11977081B2May 7, 2024
ANGPTL8 assay and uses thereof
REGENERON PHARMA0 citations52
US10582702B2Mar 10, 2020
Non-human animals having an engineered ANGPTL8 gene
REGENERON PHARMA0 citations51
US11696572B2Jul 11, 2023
Non-human animals comprising a humanized ASGR1 locus
REGENERON PHARMA0 citations50
US12209180B2Jan 28, 2025
Bis-octahydrophenanthrene carboxamide derivatives and protein conjugates thereof for use as LXR agonists
REGENERON PHARMA0 citations48